ImmunoCellular Therapeutics Ltd.
IMUC.WS
IMUC.WS was delisted on the 16th of October, 2018.
4 hedge funds and large institutions have $480K invested in ImmunoCellular Therapeutics Ltd. in 2016 Q4 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$130K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$39.9K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$31.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$416 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AFM
1
Anson Funds Management
Dallas,
Texas
| $240K | +$39.9K | +117,188 | New |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $192K | +$130K | +383,471 | New |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $47K | +$31.9K | +93,737 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $1K | +$416 | +1,222 | New |
|
IMUC.WS Hedge Fund Activity: Q4 2016 in Review
4 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics Ltd. (IMUC.WS) for Q4 2016, worth a combined $480K.
Buyers outnumbered sellers: 4 funds opened new IMUC.WS positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $130K.
- 4 institutional investors held ImmunoCellular Therapeutics Ltd. (IMUC.WS) as of Q4 2016, up from 0 in Q3 2016.
- Funds reported $480K of ImmunoCellular Therapeutics Ltd. stock for Q4 2016.
- 4 funds opened new ImmunoCellular Therapeutics Ltd. positions in Q4 2016 and 0 closed out, a net change of +4 holders.
- The largest ImmunoCellular Therapeutics Ltd. buyer in Q4 2016 was Sabby Management, an estimated $130K added.
Based on aggregated 13F filings for Q4 2016.